PharmaPendium® Adds New Module to Aid Decision Making on Drug Candidates
AMSTERDAM, May 6, 2013
AMSTERDAM, May 6, 2013 /PRNewswire/ --
PharmaPendium Metabolizing Enzymes and Transporters Module delivers
comprehensive visibility of Drug-Drug-Interactions
Elsevier , a world-leading provider of scientific, technical and medical
information products and services, today announces that PharmaPendium , the
leading source of preclinical, clinical and post-market data, has added a new
module to its content base, the Metabolizing Enzymes and Transporters Module.
The addition of the Metabolizing Enzymes and Transporters Module to
PharmaPendium's existing content gives researchers a greater understanding and
visibility of Drug-Drug Interactions (DDI) and their potential adverse
reactions during critical stages of drug discovery and development.
The new module will benefit researchers including toxicologists,
pharmacokinetics researchers and departments, safety pharmacologists and
clinical pharmacologists, who demand the highest quality data on preclinical
and clinical metabolizing enzymes and transporters. These researchers often
struggle to find comparative data to understand how changes in the activity of
metabolizing enzymes and transporters affect the safety and efficacy of drugs.
Currently, available information on DDIs is hard to collate and analyze and is
not always normalized for comparison, making data analysis not only labour and
cost intensive, but also open to critical error.
PharmaPendium's Metabolizing Enzymes and Transporters Module allows for rapid,
full text-search of literature from sources including approval documents from
the Food and Drug Administration (FDA) and European Medicines Agency (EMA). It
extracts both in vivo and in vitro human and animal experimental data on
metabolizing enzymes and transporters contained in preclinical and clinical
studies, and applies it to the context of researchers' experiments,
facilitating efficient and diligent drug development.
"Identifying potential interactions that impact the efficacy and safety of a
drug is a significant challenge," said Philip MacLaughlin, Director of Product
Development at Elsevier. "The new module supports early detection of viable
drug candidates by providing the highest quality data and enabling comparative
assessments of metabolizing enzyme and transporter activities, reducing
chances of unpredictable adverse reactions and even late stage clinical
PharmaPendium is part of Elsevier's Life Science Solutions, a suite of
interoperable, domain-specific, decision support tools which span the
discovery and development workflow, including Reaxys, Reaxys Medicinal
Chemistry, ScienceDirect, Scopus, TargetInsights, Pathway Studio and Embase.
PharmaPendium Metabolizing Enzymes and Transporters Module is available now;
for more information go to: http://www.elsevier.com/pharmapendium
PharmaPendium decision support tool allows safety assessment teams,
toxicologists, pharmacokineticists and project leaders to extract relevant
comparative pharmacological and pharmacokinetic information from the entire
history of drug development by locating published regulatory and commercial
precedents sharing similarities with the class, the target or the structural
chemistry of candidate drugs. This allows R&D organizations to make faster,
more reliable decisions about which candidate compounds to take forward to
pre-clinical phases. http://www.elsevier.com/pharmapendium
PharmaPendium® and the PharmaPendium® trademark are owned and protected by
Reed Elsevier Properties SA and used under license.
About Elsevier Elsevier is a world-leading provider of scientific, technical
and medical information products and services. The company works in
partnership with the global science and health communities to publish more
than 2,000 journals, including The Lancet and Cell , and close to 20,000 book
titles, including major reference works from Mosby and Saunders. Elsevier's
online solutions include ScienceDirect , Scopus , Reaxys , ClinicalKey and
Mosby's Suite , which enhance the productivity of science and health
professionals, and the SciVal suite and MEDai's Pinpoint Review , which help
research and health care institutions deliver better outcomes more
A global business headquartered in Amsterdam, Elsevier employs 7,000 people
worldwide. The company is part of Reed Elsevier Group plc , a world leading
provider of professional information solutions. The group employs more than
30,000 people, including more than 15,000 in North America. Reed Elsevier
Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed
Elsevier NV. Their shares are traded on the London, Amsterdam and New York
Stock Exchanges using the following ticker symbols: London: REL; Amsterdam:
REN; New York: RUK and ENL.
Media contact Liz Griffioen Elsevier +31-20-485-2247 email@example.com
Press spacebar to pause and continue. Press esc to stop.